XOMA$25.53
Chart
Performance
Key Stats
AI XOMA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyXOMA Royalty Corporation shows potential driven by its biotech royalty aggregation model and recent positive EPS surprises, but faces challenges with revenue volatility and significant net losses. Technical indicators suggest short-term weakness.
Thematic
XOMA operates in the biotech royalty sector, which benefits from innovation in healthcare. However, the specific thematic strength depends on the underlying drug development pipeline and market adoption.
Fundamental
XOMA shows fluctuating profitability with recent positive EPS surprises, but still exhibits net losses and negative P/E ratios. Revenue has been inconsistent, and the balance sheet indicates substantial debt relative to cash.
Technical
The stock is experiencing downward pressure, with most technical indicators suggesting bearish sentiment and a downtrend across various timeframes.
| Factor | Score |
|---|---|
| Biotech Innovation & Drug Development | 75 |
| Royalty Monetization | 70 |
| Healthcare Market Growth | 60 |
| Consolidation in Biotech | 65 |
| Regulatory Landscape (Pharma) | 55 |
| Factor | Score |
|---|---|
| Valuation | 30 |
| Valuation | 35 |
| Valuation | 20 |
| Profitability | 10 |
| Profitability | 80 |
| Growth | 85 |
| Balance Sheet Health | 40 |
| Balance Sheet Health | 75 |
| Cash Flow | 25 |
| Factor | Score |
|---|---|
| Trend Analysis | 20 |
| Trend Analysis | 30 |
| Momentum | 40 |
| Momentum | 50 |
| Volume Confirmation | 50 |
| Support & Resistance | 55 |
| Oscillators | 60 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive Earnings Surprises
The company has a history of beating earnings per share (EPS) estimates. For example, in Q2 2025, reported EPS was $0.06 against an estimate of -$0.30, a significant positive surprise of 120.09%.
Strong Revenue Outlook
The projected revenue for Q2 2025 has a high estimate of $10.4 million and an average estimate of $9.39 million, indicating positive expectations for top-line growth.
Bearish Points (9)
Consistent Net Losses
The company has reported net losses for the trailing twelve months (TTM) and in recent annual periods (e.g., -$13.821 million in 2024Q4, -$40.831 million in 2023Q4), indicating a lack of profitability.
High Price-to-Sales Ratio
The trailing Price-to-Sales (P/S) ratio is 41.4, and the 2024 P/S ratio is 30.8, which are exceptionally high and suggest the stock is very expensive relative to its revenue.
Calendar
October 2016
18
Next Dividend Date
January 2025
3
Ex-Dividend Date
August 2025
11
Next Earnings Date
H: $
A: $
L: $
H: 10.40M
A: 9.39M
L: 8.40M
Profile
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Seasonals
Price Target
64.67 USD
The 39 analysts offering 1 year price forecasts for XOMA have a max estimate of 104.00 and a min estimate of 35.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Leader in antibody discovery (VelocImmune platform) and development across various therapeutic areas, making it a direct technological peer and potential competitor/partner for XOMA in advanced antibody development.
Weight: 92
A major biotechnology company with extensive expertise in antibody development, a broad biologics pipeline, and a strong presence in immunology and oncology, making it a key competitor and potential acquirer/partner for companies like XOMA.
Weight: 90
A pure-play biotechnology company focused on the development of differentiated antibody therapeutics, primarily in oncology, presenting a direct competitor and peer in innovative antibody drug development.
Weight: 88
A global pharmaceutical company with a dominant presence in immunology (e.g., Humira) and oncology, heavily reliant on biologics, including antibody-based therapies, making it a significant competitor and potential partner.